17,261 trials
Prostate Cancer · Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Primary: Percentage of Participants With Confirmed Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 5; 0 Percentage of participants
Locally Advanced Rectal Cancer
Primary: Number of Participants Who Experienced Dose Limiting Toxicity (DLT) Confirmed by Safety Monitoring Committee (SMC) — 0; 1; 1; 3 Participants
Lupus Arthritis
Primary: Number of Participants With Adverse Events (AEs) — 21; 29; 25 Participants
Anaplastic Large Cell Lymphoma, ALK-Positive · Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma · Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Primary: Occurrence of Grade 3+ Non-hematologic Adverse Events — 80.6; 87.9 Percentage of patients
Skin Infection
Primary: Status of Subject's Clinical Responses — 10; 1 participants
Dry Eye
Primary: Tolerance of Test Substance Visual Analogue Scale (VAS) Score — 82.1; 87.0; 95.0; 91.1 score on a scale
Ulcerative Colitis
Primary: Clinical Remission Response Rate at Week 12 — 14.8; 16.3 Percentage of Participants — p=0.5935
Clostridium Difficile Infection Recurrence
Primary: Number of Participants With Absence of Recurrence Through Week 8 Based on Adjudication — 76; 59 Participants — p=0.0488
Metastatic Colorectal Cancer
Primary: Overall Response Rate — 0; 2; 3; 19 Participants
Major Depressive Disorder
Primary: Beck Scale for Suicide Ideation (BSS) — 9.09; 8.46; 1.9 units on a scale
Metastatic Castration-resistant Prostate Cancer
Primary: Number of Patients With Gene Alterations — 7; 4; 7; 7 Participants
Acute Myelogenous Leukemia
Primary: Median Overall Survival — 6.9 months
Glioma
Primary: Proportion of Participants With Progression-free Survival — 0.85 Proportion of participants
Plasma Cell Myeloma · Transplant-Related Carcinoma
Primary: Number of Participants With Adverse Events, Graded According to CTCAE Version 4.0 — 30 Participants
Gastroesophageal Cancer
Primary: Progression-Free Survival (PFS) — 3.8 months